Currently out of the existing stock ratings of Silvan Tuerkcan, 173 are a BUY (96.11%), 7 are a HOLD (3.89%).

Silvan Tuerkcan

Work Performance Price Targets & Ratings Chart

Analyst Silvan Tuerkcan, currently employed at JMP, carries an average stock price target met ratio of 46.7% that have a potential upside of 48.23% achieved within 145 days.

Silvan Tuerkcan’s has documented 359 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TERN, Terns Pharmaceuticals at 26-Nov-2025.

Wall Street Analyst Silvan Tuerkcan

Analyst best performing recommendations are on NUVB (NUVATION BIO).
The best stock recommendation documented was for TERN (TERNS PHARMACEUTICALS) at 10/23/2025. The price target of $15 was fulfilled within 13 days with a profit of $7.5 (100%) receiving and performance score of 76.92.

Average potential price target upside

of $82.32 (57.97%) on MNDY (MONDAY.COM LTD).
of $38.74 (61.74%) on VOR (VOR BIOPHARMA).
of $29.6 (56.87%) on GBIO (GENERATION BIO CO).

EXEL Exelixis LOGC LogicBio Therapeutics MGNX MacroGenics NTLA Intellia Therapeutics RLAY Relay Therapeutics TPTX Turning Point Therapeutics TSHA Taysha Gene Therapies CLLS Cellectis SA GBIO Generation Bio Co MRTX Mirati Ther SGEN Seagen CRSP Crispr Therapeutics AG VOR Vor Biopharma CNST Constellation Pharmaceuticals TERN Terns Pharmaceuticals BNTC Benitec Biopharma Ltd ADR MNDY Monday.Com Ltd JSPR Jasper Therapeutics ELEV Elevation Oncology ACRV Acrivon Therapeutics, Common Stock ENGN enGene Holdings Common Stock NTBL Notable Labs FHTX Foghorn Therapeutics IDYA Ideaya Biosciences NUVB Nuvation Bio SLDB Solid Biosciences LLC

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Ashwani Verma (UBS)